It has become a foot race: cash burn vs revenue growth.
I didn't hate the update, but not a lot of runs on the board either. Still clearing the decks. But as I noted before, tic toc tic toc.. their approach of totally overhauling the distribution approach is now 10months in, and so October 2021 AGM / 1H22 results will need to show something positive.
Some key things I noted:
- Revenueup ~9% to $25m (Penthrox up45% to $19m, Breathe-a-tec down 40% to $5.3m, Vet flat at $0.4m)
- Penthroxdistribution: New research around effectiveness of Penthrox;UK growing 41%; expanding Galen’s distribution from UK//Ireland to Nordicregion; new distribution in central Europe scaling up; MVP expanding salesstaff from 1 to 9 in continental Europe; Australian sales flat due to handoverof distribution back to MVP and clearing inventory; Seeking new partnership inCanada; FDA approval progressing albeit slowly with planned clinical trialprotocol to be submitted in 1H22; China trial started enrolling in 4Q21.
- Spacesaver: Walmart private label finally launched in FY21; General slowdown due toCovid; impairment of $4.7m goodwill; not expecting significant growth - so much for being the cash cow to fund expansion in Penthrox.
- Continuous Flow: Lidocaine stillthe most advanced, but “no licenses have been achieved, making reliableestimation of the technology’s value-in-use difficult”, $4.3m impairment. I have noted before I assume this is worth $0 even though it could have significant upside, operationally just been too difficult.
- Cash flow: $36m in cash reservesafter the recent raise; growth CAPEX of $15m in FY21; new distribution means gross profits up ($15 to 19m) but so are admin expenses ($4 to $14m); tictoc. This will become a real issue in FY22 when admin expenses grow with new MVP distribution team in Europe and Australia.
- Outlook: Expecting strongEuropean Penthroxsales growth - but this probably needs to be +$7m in 1H22 just to cover the additional distribution costs.
- Next report will beOctober 2021 at the AGM.
- Forums
- ASX - By Stock
- MVP
- Ann: Preliminary Final Report and Full Year Accounts
Ann: Preliminary Final Report and Full Year Accounts, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MVP (ASX) to my watchlist
(20min delay)
|
|||||
Last
43.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.44M |
Open | High | Low | Value | Volume |
43.0¢ | 44.0¢ | 43.0¢ | $6.872K | 15.74K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 28506 | 43.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
44.0¢ | 6327 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 28506 | 0.430 |
2 | 3552 | 0.425 |
1 | 2380 | 0.420 |
1 | 9572 | 0.415 |
1 | 1207 | 0.410 |
Price($) | Vol. | No. |
---|---|---|
0.440 | 6327 | 1 |
0.445 | 6742 | 1 |
0.450 | 130 | 1 |
0.460 | 2500 | 1 |
0.470 | 1642 | 1 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
MVP (ASX) Chart |